Scarica l'app Stockscreener
25.50
0.16%
0.04
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Q1 Earnings Estimate for NAMS Issued By Leerink Partnrs - Defense World
(NAMSW) Technical Data - Stock Traders Daily
Nap B.V. Forgrowth Sells 100,728 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Newamsterdam Pharma sees $4.07 million in stock sales by Forbion funds - Investing.com
What is Leerink Partnrs' Estimate for NAMS Q1 Earnings? - MarketBeat
What is Leerink Partnrs’ Estimate for NAMS Q4 Earnings? - Defense World
Q4 Earnings Forecast for NAMS Issued By Leerink Partnrs - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownWhat's Next? - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.7%Here's What Happened - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 Shares - MarketBeat
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg-프린트화면 - The Korea Herald
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg - The Manila Times
NewAmsterdam Pharma (NASDAQ:NAMS) Enters into Underwriting Agreement for Public OfferingNEW YORK–(BUSINESS WIRE)– December 13, 2024– NewAmsterdam Pharma Company N.V. (NAMS) announced today the completion of an underwritten pub - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Short Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Rises By 156.4% - Defense World
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
NewAmsterdam Pharma Secures Massive $479M in Upsized Public Offering, Strengthens Financial Position - StockTitan
NewAmsterdam Pharma’s $452.6M Public Offering Success - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Fmr LLC - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Fmr LLC Buys 86,712 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Newamsterdam Pharma Company (NAMS)Thursday, Sep 12, 2024 - Smartkarma
NewAmsterdam Pharma shares supported by de-risked obicetrapib approval and MACE reduction - Investing.com Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Announces Positive Topline Data from Phase 3 BROADWAY Clinical Trial - Defense World
NewAmsterdam Pharma Launches Massive $416.5M Public Offering with Upsized Share Sale - StockTitan
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 - GlobeNewswire
Shares of New Amsterdam (NAMS) climb after phase III data exceeds expectations - substack.com
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam leaps on positive trial results - The Pharma Letter
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
NewAmsterdam reports positive Phase 3 trial results for CVD drug By Investing.com - Investing.com South Africa
NewAmsterdam Pharma halts $150 million share sale plan By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma halts $150 million share sale plan - Investing.com India
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - 24matins.uk
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug - Yahoo! Voices
NewAmsterdam Pharma Announces Commencement of $300 Million - GlobeNewswire
NewAmsterdam Pharma Launches Massive $300M Public Offering with Pre-Funded Warrants - StockTitan
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Benzinga
NewAmsterdam reports positive Phase 3 trial results for CVD drug - Investing.com India
NewAmsterdam's drug shows promise in lowering LDL-C - Investing.com
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - The Manila Times
NewAmsterdam Pharma Announces Positive Topline Data from - GlobeNewswire
NewAmsterdam Pharma's Phase 3 Trial Shows Breakthrough 33% Cholesterol Reduction in Heart Disease Patients - StockTitan
Frazier Life Sciences Management L.P. Buys 628,251 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Walleye Capital LLC Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Inducement Share Options to New Executives Under 2024 Plan - StockTitan
Readystate Asset Management LP Invests $2.01 Million in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma - Benzinga
Where are the Opportunities in (NAMS) - Stock Traders Daily
Parkman Healthcare Partners LLC Sells 30,042 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Cinctive Capital Management LP Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
ArrowMark Colorado Holdings LLC Boosts Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):